X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (396) 396
Paper (317) 317
Publication (214) 214
Report (113) 113
Newspaper Article (19) 19
Data Set (7) 7
Patent (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (357) 357
particle physics (317) 317
high energy physics - experiment (306) 306
physics (304) 304
physics - high energy physics - experiment (298) 298
cern lhc coll (263) 263
high energy physics (250) 250
experimental results (249) 249
hep (207) 207
p p: scattering (183) 183
p p: colliding beams (171) 171
phenomenology (165) 165
13000 gev-cms (164) 164
ex (156) 156
nuclear experiment (114) 114
physics of elementary particles and fields (113) 113
atlas (91) 91
scattering [p p] (80) 80
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (76) 76
colliding beams [p p] (75) 75
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (70) 70
subatomic physics (70) 70
subatomär fysik (70) 70
background (62) 62
fysik (60) 60
natural sciences (60) 60
naturvetenskap (60) 60
physical sciences (60) 60
8000 gev-cms (54) 54
hadron-hadron scattering (53) 53
astrophysics (52) 52
mass dependence (50) 50
particle physics - experiment (49) 49
high energy astrophysical phenomena (43) 43
物理学 (42) 42
bottom: particle identification (41) 41
data analysis method (36) 36
z0: leptonic decay (35) 35
jet: bottom (34) 34
transverse momentum dependence (34) 34
physics, particles & fields (33) 33
channel cross section: branching ratio: upper limit (32) 32
differential cross section: measured (32) 32
final state:jet lepton (32) 32
channel cross section: upper limit (31) 31
rapidity dependence (30) 30
transverse momentum: missing-energy (30) 30
mass spectrum: (29) 29
cern lab (28) 28
hep-ex (28) 28
top: pair production (28) 28
numerical calculations: monte carlo (26) 26
channel cross section: measured (25) 25
final state:jet dilepton (24) 24
elementary particles, quantum field theory (23) 23
higgs particle: hadroproduction (23) 23
quantum field theories, string theory (23) 23
electroweak interaction (22) 22
kinematics (22) 22
large hadron collider (22) 22
phase space (22) 22
astronomy, astrophysics and cosmology (21) 21
ciências físicas [ciências naturais] (21) 21
nuclear and particle physics. atomic energy. radioactivity (21) 21
science & technology (21) 21
higgs particle: hadronic decay (20) 20
instrumentation and detectors (20) 20
w: leptonic decay (20) 20
bottom: pair production (19) 19
final state:jet (19) 19
jet: transverse momentum (19) 19
sensitivity (19) 19
supersymmetry (19) 19
w: hadronic decay (19) 19
collisions (18) 18
leptonic decay [z0] (18) 18
measurement science and instrumentation (18) 18
nucl (18) 18
nuclear energy (18) 18
nuclear physics, heavy ions, hadrons (18) 18
quantum chromodynamics: perturbation theory (18) 18
nuclear physics (17) 17
measured [differential cross section] (16) 16
missing-energy [transverse momentum] (16) 16
resonance: production (16) 16
z0: pair production (16) 16
muon: pair production (15) 15
structure (15) 15
transverse momentum (15) 15
w: associated production (15) 15
z0: associated production (15) 15
benchmark (14) 14
coupling constant: upper limit (14) 14
dijet (14) 14
higher-order: 1 (14) 14
monte carlo [numerical calculations] (14) 14
regular - experimental physics (14) 14
detectors (13) 13
electron: pair production (13) 13
hadron (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article
by Aaboud, M and Aad, G and Abbott, B and Abdinov, O and Abeloos, B and Abidi, S H and AbouZeid, O S and Abraham, N L and Abramowicz, H and Abreu, H and Abreu, R and Abulaiti, Y and Acharya, B S and Adachi, S and Adamczyk, L and Adelman, J and Adersberger, M and Adye, T and Affolder, A A and Afik, Y and Agatonovic-Jovin, T and Agheorghiesei, C and Aguilar-Saavedra, J A and Ahlen, S P and Ahmadov, F and Aielli, G and Akatsuka, S and Akerstedt, H and Åkesson, T P. A and Akilli, E and Akimov, A V and Alberghi, G L and Albert, J and Albicocco, P and Alconada Verzini, M J and Alderweireldt, S C and Aleksa, M and Aleksandrov, I N and Alexa, C and Alexander, G and Alexopoulos, T and Alhroob, M and Ali, B and Aliev, M and Alimonti, G and Alison, J and Alkire, S P and Allbrooke, B M. M and Allen, B W and Allport, P P and Aloisio, A and Alonso, A and Alonso, F and Alpigiani, C and Alshehri, A A and Alstaty, M I and Alvarez Gonzalez, B and Álvarez Piqueras, D and Alviggi, M G and Amadio, B T and Amaral Coutinho, Y and Amelung, C and Amidei, D and Amor Dos Santos, S P and Amoroso, S and Amundsen, G and Anastopoulos, C and Ancu, L S and Andari, N and Andeen, T and Anders, C F and Anders, J K and Anderson, K J and Andreazza, A and Andrei, V and Angelidakis, S and Angelozzi, I and Angerami, A and Anisenkov, A V and Anjos, N and Annovi, A and Antel, C and Antonelli, M and Antonov, A and Antrim, D J and Anulli, F and Aoki, M and Aperio Bella, L and Arabidze, G and Arai, Y and Araque, J P and Araujo Ferraz, V and Arce, A T. H and Ardell, R E and Arduh, F A and Arguin, J-F and Argyropoulos, S and Arik, M and Armbruster, A J and Armitage, L J and ... and ATLAS Collaboration and The ATLAS collaboration and SLAC National Accelerator Lab., Menlo Park, CA (United States) and Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States) and Oak Ridge National Laboratory, Oak Ridge Leadership Computing Facility (OLCF) and Partikel- och astropartikelfysik and Skolan för teknikvetenskap (SCI) and KTH and Fysik
Journal of High Energy Physics, ISSN 1126-6708, 1/2018, Volume 2018, Issue 1, pp. 1 - 53
Journal Article
by Aaboud, M and Aad, G and Abbott, B and Abdinov, O and Abeloos, B and Abhayasinghe, D.K and Abidi, S.H and AbouZeid, O.S and Abraham, N.L and Abramowicz, H and Abreu, H and Abulaiti, Y and Acharya, B.S and Adachi, S and Adamczyk, L and Adelman, J and Adersberger, M and Adiguzel, A and Adye, T and Affolder, A.A and Afik, Y and Agheorghiesei, C and Aguilar-Saavedra, J.A and Ahmadov, F and Aielli, G and Akatsuka, S and Åkesson, T.P.A and Akilli, E and Akimov, A.V and Alberghi, G.L and Albert, J and Albicocco, P and Alconada Verzini, M.J and Alderweireldt, S and Aleksa, M and Aleksandrov, I.N and Alexa, C and Alexopoulos, T and Alhroob, M and Ali, B and Aliev, M and Alimonti, G and Alison, J and Alkire, S.P and Allaire, C and Allbrooke, B.M.M and Allen, B.W and Allport, P.P and Aloisio, A and Alonso, A and Alonso, F and Alpigiani, C and Alshehri, A.A and Alstaty, M.I and Alvarez Gonzalez, B and Álvarez Piqueras, D and Alviggi, M.G and Amadio, B.T and Amaral Coutinho, Y and Ambroz, L and Amelung, C and Amidei, D and Amor Dos Santos, S.P and Amoroso, S and Amrouche, C.S and Anastopoulos, C and Ancu, L.S and Andari, N and Andeen, T and Anders, J.K and Anders, C.F and Anderson, K.J and Andreazza, A and Andrei, V and Anelli, C.R and Angelidakis, S and Angelozzi, I and Angerami, A and Anisenkov, A.V and Annovi, A and Antel, C and Anthony, M.T and Antonelli, M and Antrim, D.J.A and Anulli, F and Aoki, M and Aperio Bella, L and Arabidze, G and Araque, J.P and Araujo Ferraz, V and Araujo Pereira, R and Arce, A.T.H and Ardell, R.E and Arduh, F.A and Arguin, J-F and Argyropoulos, S and Armbruster, A.J and Armitage, L.J and Armstrong, A and Arnaez, O and ... and ATLAS Collaboration and Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States) and Partikel- och astropartikelfysik and Skolan för teknikvetenskap (SCI) and KTH and Fysik
Physics Letters B, ISSN 0370-2693, 09/2018, Volume 784, Issue C, pp. 173 - 191
The observation of Higgs boson production in association with a top quark pair ( ), based on the analysis of proton–proton collision data at a centre-of-mass... 
PHYSICS, NUCLEAR | SEARCH | ASTRONOMY & ASTROPHYSICS | PHYSICS, PARTICLES & FIELDS | Physics - High Energy Physics - Experiment | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS | Fysik | Subatomär fysik | Physical Sciences | Subatomic Physics | Naturvetenskap | Natural Sciences
Journal Article
by Aaboud, M and Aad, G and Abbott, B and Abdallah, J and Abdinov, O and Abeloos, B and Aben, R and Abouzeid, O.S and Abraham, N.L and Abramowicz, H and Abreu, H and Abreu, R and Abulaiti, Y and Acharya, B.S and Adamczyk, L and Adams, D.L and Adelman, J and Adomeit, S and Adye, T and Affolder, A.A and Agatonovic-Jovin, T and Agricola, J and Aguilar-Saavedra, J.A and Ahlen, S.P and Ahmadov, F and Aielli, G and Akerstedt, H and Åkesson, T.P.A and Akimov, A.V and Alberghi, G.L and Albert, J and Albrand, S and Alconada Verzini, M.J and Aleksa, M and Aleksandrov, I.N and Alexa, C and Alexander, G and Alexopoulos, T and Alhroob, M and Ali, B and Aliev, M and Alimonti, G and Alison, J and Alkire, S.P and Allbrooke, B.M.M and Allen, B.W and Allport, P.P and Aloisio, A and Alonso, A and Alonso, F and Alpigiani, C and Alstaty, M and Alvarez Gonzalez, B and Álvarez Piqueras, D and Alviggi, M.G and Amadio, B.T and Amako, K and Amaral Coutinho, Y and Amelung, C and Amidei, D and Amor Dos Santos, S.P and Amorim, A and Amoroso, S and Amundsen, G and Anastopoulos, C and Ancu, L.S and Andari, N and Andeen, T and Anders, C.F and Anders, G and Anders, J.K and Anderson, K.J and Andreazza, A and Andrei, V and Angelidakis, S and Angelozzi, I and Anger, P and Angerami, A and Anghinolfi, F and Anisenkov, A.V and Anjos, N and Annovi, A and Antel, C and Antonelli, M and Antonov, A and Anulli, F and Aoki, M and Aperio Bella, L and Arabidze, G and Arai, Y and Araque, J.P and Arce, A.T.H and Arduh, F.A and Arguin, J.-F and Argyropoulos, S and Arik, M and Armbruster, A.J and Armitage, L.J and Arnaez, O and Arnold, H and ...
Physical Review C, ISSN 2469-9985, 06/2017, Volume 95, Issue 6
Two-particle pseudorapidity correlations are measured in root s(NN) = 2.76 TeV Pb + Pb, root s(NN) = 5.02 TeV p+Pb, and root s = 13 TeV pp collisions at the... 
TRANSVERSE-MOMENTUM | SIDE | LONG-RANGE | ANGULAR-CORRELATIONS | TEV | UNDERLYING EVENT | PHYSICS, NUCLEAR | CHARGED-PARTICLE DISTRIBUTIONS | PP COLLISIONS | PB COLLISIONS | DEPENDENCE
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2011, Volume 125, Issue 2, pp. 447 - 455
To determine the feasible dose and schedule for everolimus, an oral mTOR inhibitor, combined with vinorelbine and trastuzumab for patients with... 
HER2-overexpressing metastatic breast cancer | Phase I | Medicine & Public Health | mTOR | Oncology | Everolimus | Trastuzumab | Vinorelbine | ACTIVATION | PLUS VINORELBINE | DOCETAXEL | CHEMOTHERAPY | RAD001 EVEROLIMUS | ONCOLOGY | CLINICAL-TRIALS | RESISTANCE | LETROZOLE | 1ST-LINE THERAPY | HER2 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Vinblastine - administration & dosage | Vinblastine - therapeutic use | Breast Neoplasms - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Vinblastine - analogs & derivatives | Adult | Female | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 | Survival Analysis | Aged | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Metastasis | Antineoplastic agents | Index Medicus
Journal Article